Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Medicenna Therapeutics Corp. will showcase new clinical and preclinical immunotherapy data at the upcoming SITC conference, including updates on their MDNA11 study for treating advanced solid tumors and novel findings on MDNA113 and IL-2 agonists for glioblastoma. The data promise to enhance understanding of their therapies’ efficacy and tumor-targeting capabilities.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.